Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: Comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001

Antiviral Therapy

Volumn 19, Issue 2, 2014, Pages 179-189

  Maeda, Kenji ^a   Desai, Darshan V ^a   Aoki, Manabu ^b,c   Nakata, Hirotomo ^a,c   Kodama, Eiichi N ^d   Mitsuya, Hiroaki ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; CENSAVUDINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; 4'-ETHYNYL-2-FLUORO-2'-DEOXYADENOSINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS-986001; DEOXYADENOSINE DERIVATIVE; DEOXYCYTIDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; THYMIDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS ISOLATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; METABOLISM; MOLECULAR GENETICS; VIROLOGY;

ADENINE; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DEOXYADENOSINES; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE, VIRAL; EMTRICITABINE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; ORGANOPHOSPHONATES; TENOFOVIR; THYMIDINE;

EID: 84898605670     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2697     Document Type: Article

References (35)

1. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathyassociated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
2. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33:307-320.
3. Maeda K, Das D, Mitsuya H. Development of antiviral therapeutics for HIV-1 infection and AIDS. In Hall JC, Hall BJ, Cockerell CJ (Editors). HIV/AIDS in the post-HAART era: manifestations, treatment & epidemiology. Shelton, CT: People's Medical Publishing House 2011; pp. 900-937.
4. Tsibris AM, Hirsch MS. Antiretroviral therapy in the clinic. J Virol 2010; 84:5458-5464.
5. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26:1261-1268.
6. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
7. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72:e1-e25.
8. Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 2013; 98:93-120.
9. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. Aids Res Treat 2011; 2011:354908.
10. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment -case report and review of literature. J Infect 2005; 51:E61-E65.
11. Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep 2012; 9:218-222.
12. Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22-33.
13. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009; 3:583-594.
14. Kawamoto A, Kodama E, Sarafianos SG, et al. 2'-Deoxy-4'-C-ethynyl-2-halo-Adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 2008; 40:2410-2420.
15. Kodama EI, Kohgo S, Kitano K, et al. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45:1539-1546.
16. Nakata H, Amano M, Koh Y, et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother 2007; 51:2701-2708.
17. Murphey-Corb M, Rajakumar P, Michael H, et al. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother 2012; 56:4707-4712.
18. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mitsuya H. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 2004; 78:12030-12040.
19. Yoshimura K, Kato R, Yusa K, et al. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A 1999; 96:8675-8680.
20. Ohrui H. 2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec 2006; 6:133-143.
21. Nitanda T, Wang X, Kumamoto H, et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. Antimicrob Agents Chemother 2005; 49:3355-3360.
22. Koh Y, Amano M, Towata T, et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol 2010; 84:11961-11969.
23. Maeda K, Yoshimura K, Shibayama S, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 276:35194-35200.
24. Aoki M, Danish ML, Aoki-Ogata H, et al. The loss of protease dimerization inhibition activity of tipranavir (TPV) and its association with HIV-1 acquisition of resistance to TPV. J Virol 2012; 86:13384-13396.
25. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 1996; 93:6106-6111.
26. Yusa K, Kavlick MF, Kosalaraksa P, Mitsuya H. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res 1997; 36:179-189.
27. Michailidis E, Marchand B, Kodama EN, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocationdefective reverse transcriptase inhibitor. J Biol Chem 2009; 284:35681-35691.
28. Hattori S, Ide K, Nakata H, et al. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-Transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 2009; 53:3887-3893.
29. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 2010; 6:e1001005.
30. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
31. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60:885-888.
32. Imamichi T, Sinha T, Imamichi H, et al. High-level resistance to 3'-Azido-3'-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000; 74:1023-1028.
33. Imamichi T, Berg SC, Imamichi H, et al. Relative replication fitness of a high-level 3'-Azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-To-Gly) at codon 69. J Virol 2000; 74:10958-10964.
34. Imamichi T, Murphy MA, Imamichi H, Lane HC. Amino acid deletion at codon 67 and Thr-To-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistant profiles. J Virol 2001; 75:3988-3992.
35. Kisic M, Matamoros T, Nevot M, et al. Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J Biol Chem 2011; 286:20615-20624.